Intended for UK healthcare professionals

Basics

Introducing Supemtek
Recombinant technology
Efficacy
Comparison versus standard influenza vaccines

Click here to download more information on Supemtek

Supemtek Prescribing Information

Visit Vaxishop

Supemtek's clinical data and safety profile

Watch the video to find out more about Supemtek's clinical data
and safety profile.

Watch Now

RECOMBINANT TECHNOLOGY

Recombinant technology eliminates the possibility of adaptation or mutation by replicating only the haemagglutinin (HA) antigen direct from a genetic sequence. The resulting antigens are an exact genetic match to the target strain HA antigen.3,6

Find out more about the recombinant technology used to manufacture Supemtek here

INCREASED HA CONTENT

Supemtek contains 3x more HA antigen (45 mcg versus 15 mcg) per strain, compared with cell-
and egg-based standard-dose quadrivalent influenza vaccines.3

EFFICACY

Supemtek demonstrated 30% greater relative efficacy (1% absolute efficacy) versus standard-dose egg-based quadrivalent inactivated influenza vaccine (QIVe), in preventing confirmed cases of influenza-like illness in adults ≥50 years of age, with respective influenza attack rates of
2.2% and 3.2 %.†3

Find out more about the clinical data for Supemtek here

COMPARABLE SAFETY PROFILE

Supemtek demonstrated a comparable safety profile to standard-dose egg-based QIVe.3,7

Find out more about the safety profile of Supemtek here

SUPPORTED BY RANDOMISED CONTROLLED TRIALS

Randomised controlled trials support the efficacy and safety of Supemtek for active immunisation for the prevention of influenza disease in adults ≥18 years of age.3,7

Find out more about the clinical development of Supemtek here

COMPARISON VERSUS STANDARD INFLUENZA VACCINES

Results from a European Centre for Disease Prevention and Control (ECDC) systematic literature review to assess the efficacy, effectiveness and safety of enhanced influenza vaccines (versus standard-dose or placebo) for the prevention of laboratory-confirmed influenza in adults ≥18 years of age suggested that Supemtek may offer ”better protection than no vaccination, or standard influenza vaccines.”(QIVe)8

Find out more about the results of the review here

Vaccination Live

Discover More